PCVX IPOs 18.0M* shares @$16.00: https://www.globenewswire.com/news-release/2020/06/12/2047236/0/en/Vaxcyte-Announces-Pricing-of-Upsized-Initial-Public-Offering.html Vaxcyte, formerly known as SutroVax, is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. …In addition to its pneumococcal conjugate vaccines in development, VAX-24 and VAX-XP, Vaxcyte is leveraging its proprietary platform to advance other novel vaccines, including a prophylactic vaccine to prevent Group A Strep infections (VAX-A1) and a therapeutic vaccine to treat periodontal disease (VAX-PG). *Assuming exercise of underwriter’s option.